Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells
Articles > Article · 2009
Authors: BÜLENT KARABULUT, C. ERTEN, M. K. GUL, E. CENGIZ, Betül KARACA, Y. KUCUKZEYBEK, G. GORUMLU, H. Atmaca, S. Uzunoglu, Ulus Ali ŞANLI, Y. Baran, RÜÇHAN USLU
CELL BIOLOGY INTERNATIONAL, Journal Indexed in SCI Expanded, International, 2009, vol 33, pp 239-246
DOI: 10.1016/j.cellbi.2008.11.011
Summary
Docetaxel, a semi-synthetic taxane analogue, is used effectively in the treatment of metastatic prostate cancer. Zoledronic acid, the most potent member of bisphosphonates, has shown pleiotropic anti-tumoral effects on prostate cancer cells. We have explored the possible additive/synergistic effects and the apoptotic pathways induced by combination treatment of docetaxel and zoledronic acid in hormone and drug refractory, PC-3 and DU-145 prostate cancer cells. Combination of docetaxel and zoledronic acid synergistically inhibits cell growth in PC-3 and DU-145 cells. Moreover, this effect was due to downregulation of antiapoptotic protein Bcl-2 in PC-3 and DU-145 cells. In conclusion, docetaxel/zoledronic acid combination is potentially a novel and effective approach for the treatment of prostate cancer. (C) 2008 International Federation for Cell Biology. Published by Elsevier Ltd. All rights reserved.